JPWO2023028575A5 - - Google Patents
Info
- Publication number
- JPWO2023028575A5 JPWO2023028575A5 JP2024513011A JP2024513011A JPWO2023028575A5 JP WO2023028575 A5 JPWO2023028575 A5 JP WO2023028575A5 JP 2024513011 A JP2024513011 A JP 2024513011A JP 2024513011 A JP2024513011 A JP 2024513011A JP WO2023028575 A5 JPWO2023028575 A5 JP WO2023028575A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- modified
- oligomeric compound
- modified oligonucleotide
- internucleoside linkage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163237898P | 2021-08-27 | 2021-08-27 | |
| US63/237,898 | 2021-08-27 | ||
| PCT/US2022/075493 WO2023028575A2 (en) | 2021-08-27 | 2022-08-26 | Compounds and methods for modulating scn1a expression |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024534157A JP2024534157A (ja) | 2024-09-18 |
| JPWO2023028575A5 true JPWO2023028575A5 (https=) | 2025-09-02 |
| JP2024534157A5 JP2024534157A5 (https=) | 2025-09-02 |
Family
ID=85322277
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024513011A Pending JP2024534157A (ja) | 2021-08-27 | 2022-08-26 | Ｓｃｎ１ａ発現を調節するための化合物及び方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240360449A1 (https=) |
| EP (1) | EP4392562A4 (https=) |
| JP (1) | JP2024534157A (https=) |
| KR (1) | KR20240049349A (https=) |
| CN (1) | CN118451183A (https=) |
| AU (1) | AU2022334739A1 (https=) |
| CA (1) | CA3230299A1 (https=) |
| IL (1) | IL310811A (https=) |
| MX (1) | MX2024002553A (https=) |
| WO (1) | WO2023028575A2 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210134003A (ko) | 2019-02-27 | 2021-11-08 | 스톡 테라퓨틱스, 인크. | 병태 및 질환의 치료를 위한 안티센스 올리고머 |
| BR112022022889A2 (pt) | 2020-05-11 | 2023-04-04 | Stoke Therapeutics Inc | Oligômeros antissentido de opa1 para tratamento de condições e doenças |
| CN116334086A (zh) * | 2023-03-29 | 2023-06-27 | 广州医科大学附属第二医院 | 一种用于修复或抑制SCN1A基因异常剪接的U1-snRNA及其用途 |
| WO2025024568A1 (en) * | 2023-07-24 | 2025-01-30 | Stoke Therapeutics, Inc. | Methods for treating conditions and diseases |
| WO2026052819A1 (en) * | 2024-09-06 | 2026-03-12 | Ospedale San Raffaele S.R.L. | Gene therapy |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202001590RA (en) * | 2017-08-25 | 2020-03-30 | Stoke Therapeutics Inc | Antisense oligomers for treatment of conditions and diseases |
| US20220372489A1 (en) * | 2019-06-21 | 2022-11-24 | Quralis Corporation | Ppm1a inhibitors and methods of using same |
| EP4013767A4 (en) * | 2019-08-15 | 2023-10-25 | Ionis Pharmaceuticals, Inc. | Linkage modified oligomeric compounds and uses thereof |
| BR112022010882A2 (pt) * | 2019-12-06 | 2022-10-04 | Stoke Therapeutics Inc | Oligômeros antissenso para tratamento de condições e doenças |
| WO2021174036A1 (en) * | 2020-02-28 | 2021-09-02 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating scn1a expression |
-
2022
- 2022-08-26 EP EP22862285.8A patent/EP4392562A4/en active Pending
- 2022-08-26 AU AU2022334739A patent/AU2022334739A1/en active Pending
- 2022-08-26 CA CA3230299A patent/CA3230299A1/en active Pending
- 2022-08-26 KR KR1020247009728A patent/KR20240049349A/ko active Pending
- 2022-08-26 US US18/685,362 patent/US20240360449A1/en active Pending
- 2022-08-26 WO PCT/US2022/075493 patent/WO2023028575A2/en not_active Ceased
- 2022-08-26 JP JP2024513011A patent/JP2024534157A/ja active Pending
- 2022-08-26 MX MX2024002553A patent/MX2024002553A/es unknown
- 2022-08-26 IL IL310811A patent/IL310811A/en unknown
- 2022-08-26 CN CN202280065211.6A patent/CN118451183A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6292631B2 (ja) | 含窒素複素環構造を有するヌクレオシド及びヌクレオチド | |
| JP2020193199A5 (https=) | ||
| JP5669073B2 (ja) | 架橋型人工ヌクレオシドおよびヌクレオチド | |
| AU682576B2 (en) | Nucleosides and oligonucleotides having 2'-ether groups | |
| Seth et al. | An exocyclic methylene group acts as a bioisostere of the 2′-oxygen atom in LNA | |
| CA3098624A1 (en) | Oligonucleotide compositions and methods of use thereof | |
| JP2019529489A5 (https=) | ||
| JPWO2014112463A1 (ja) | スルホンアミド構造を有するヌクレオシドおよびヌクレオチド | |
| US20160215288A1 (en) | Organic compounds to treat hepatitis b virus | |
| Pradeepkumar et al. | Synthesis, Physicochemical and Biochemical Studies of 1 ‘, 2 ‘-Oxetane Constrained Adenosine and Guanosine Modified Oligonucleotides, and Their Comparison with Those of the Corresponding Cytidine and Thymidine Analogues | |
| CN119790152A (zh) | 使用unc13a基因转录本的调节剂治疗神经系统疾病 | |
| KR20240049349A (ko) | Scn1a 발현을 조절하기 위한 화합물 및 방법 | |
| JP2021515784A (ja) | 修飾オリゴヌクレオチド及びタウオパチーにおける使用方法 | |
| RU2020127049A (ru) | Модуляторы экспрессии dnm2 | |
| CN119522282A (zh) | 具有经修饰的主链化学的剪接转换器反义寡核苷酸 | |
| JPWO2023028575A5 (https=) | ||
| WO2017142054A1 (ja) | 人工ヌクレオシド及び人工ヌクレオチド並びに人工オリゴヌクレオチド | |
| JPWO2019241648A5 (https=) | ||
| US20220127300A1 (en) | 5'-modified nucleoside and nucleotide using same | |
| TW202140788A (zh) | 用於調節ｓｃｎ１ａ表現之化合物及方法 | |
| WO2015125845A1 (ja) | 含窒素非芳香族複素環を含む核酸のリン酸部位修飾 | |
| JPWO2020205463A5 (https=) | ||
| JPWO2022026589A5 (https=) | ||
| CN119452086A (zh) | 具有修饰的主链化学的gapmer反义寡核苷酸 | |
| JPWO2022032060A5 (https=) |